Welcome

Sign out Have a question? We're here to help

Sign out

Vistagen Therap. Com (VTGN)

$0.39 0.01 (2.60%)

17:01 EDT VTGN Stock Quote Delayed 20 Minutes

Volume:

Previous Close -

Market Cap 8.98M

PE Ratio -0.35

EPS -1.12

Volume (Avg. Vol.) 179,100

Day's Range 0.36 - 0.42

52-Week Range 0.29 - 1.49

Dividend & Yield N/A (N/A)

VTGN Stock Predictions, Articles, and Vistagen Therap. Com News

From InvestorPlace
From the Web

Why Vistagen Therapeutics Inc Stock Is Going Wild Today

By William White, InvestorPlace Writer May 25, 2018

Vistagen Therapeutics (VTGN) stock was flying high on Friday following news that it is being covered by another research firm,

VistaGen Therapeutics inks $10M stock purchase agreement; shares up 13% premarket

From Seeking Alpha Mar 25, 2020

VistaGen Therapeutics (OTC:VTGN) announces a common stock purchase agreement with Lincoln Park Capital Fund, for up to $10.25M. Under the agreement, LPC made an initial purchase of $250,000 of VistaG

VistaGen up 15% premarket on positive PH10 data

From Seeking Alpha Feb 20, 2020

Nano cap VistaGen Therapeutics (NASDAQ:VTGN) jumps 15% premarket on increased volume in response to positive results from a single-site, 30-subject Phase 2a clinical trial evaluating PH10, a rapid-ons

VistaGen on go with mid-stage study of AV-101 in Parkinson's; shares up 8%

From Seeking Alpha Jan 30, 2020

Nano cap VistaGen Therapeutics (VTGN +7.7%) is up on increased volume in reaction to its announcement that the FDA has signed off on its IND for a Phase 2 clinical trial evaluating NMDA glutamate rece

VistaGen +19% premarket on positive AV-101 results

From Seeking Alpha Dec 19, 2019

VistaGen Therapeutics (NASDAQ:VTGN) is up 19% premarket on announcing successful results from a first-step, Phase 1b clinical study with healthy U.S. military Veterans, which measured NMDAR (N-methyl-

UL, CLVS among premarket losers

From Seeking Alpha Dec 17, 2019

Proteostasis Therapeutics (NASDAQ:PTI) -37% on mixed results in mid-stage CF study.MEI Pharma (NASDAQ:MEIP) -28% on pricing stock offering.VistaGen Therapeutics (NASDAQ:VTGN) -9%.The Unilever Group (N

VistaGen Up on Fast Track Designation for Anxiety Disorder Drug

From Zacks Investment Research Dec 11, 2019

The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.

Navellier Ratings

Total Grade

Buy

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Welcome

Vistagen Therap. Com (VTGN)

Navellier Ratings

Total Grade

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Already a subscriber?

Welcome

Vistagen Therap. Com (VTGN)

VTGN Stock Predictions, Articles, and Vistagen Therap. Com News

Why Vistagen Therapeutics Inc Stock Is Going Wild Today

VistaGen Therapeutics inks $10M stock purchase agreement; shares up 13% premarket

VistaGen up 15% premarket on positive PH10 data

VistaGen on go with mid-stage study of AV-101 in Parkinson's; shares up 8%

VistaGen +19% premarket on positive AV-101 results

UL, CLVS among premarket losers

VistaGen Up on Fast Track Designation for Anxiety Disorder Drug

Navellier Ratings

Total Grade

Subscriber Sign in